天大药业发布中期业绩 股东应占亏损3323.7万港元 同比扩大22.03%

Core Viewpoint - Tian Da Pharmaceutical (00455) reported a decline in revenue and an increase in losses for the first half of 2025, indicating financial challenges for the company [1] Financial Performance - The company achieved revenue of HKD 137 million, representing a year-on-year decrease of 12.45% [1] - The loss attributable to shareholders was HKD 33.237 million, which expanded by 22.03% compared to the previous year [1] - The basic loss per share was HKD 0.0155 [1]